ORIGINAL RESEARCH article
Front. Mol. Biosci.
Sec. Molecular Diagnostics and Therapeutics
Volume 12 - 2025 | doi: 10.3389/fmolb.2025.1614311
This article is part of the Research TopicExploring the Correlation and Heterogeneity Between Acute and Chronic Diseases: Diagnostic and Therapeutic PerspectivesView all 5 articles
A Nomogram Model Based on Tumor Necrosis Factor-Like Ligand 1A(TL1A) and Death Receptor-3(DR3) Promoter Methylation for Predicting 90-Day Prognosis in Patients with HBV-Associated Acute-on-Chronic Liver Failure
Provisionally accepted
- Qilu Hospital, Shandong University, Jinan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Acute-on-chronic liver failure (ACLF) associated with hepatitis-B-virus (HBV) is a life-threatening condition characterized by severe hepatic dysfunction. The TL1A/DR3 signaling axis modulates immune responses and contributes to hepatic inflammation. This study aimed to investigate the methylation level of TL1A/DR3 promoter, explore its ability to predict prognosis, and establish a prognostic model combined with clinical indicators.Methylation status and gene expression of TL1A and DR3 were analyzed in peripheral blood mononuclear cells (PBMCs) from 714 participants using Methylight and quantitative polymerase chain reaction (qPCR).Univariate, LASSO, and multivariate analyses were performed to identify key prognostic factors for 90-day outcomes in patients with HBV-associated acute-on-chronic liver failure (HBV-ACLF) and develop corresponding prognostic models. Model performance, including calibration and clinical utility, was evaluated using receiver operating characteristic (ROC) curves, Hosmer-Lemeshow (H-L) tests, and decision curve analysis (DCA). A visual nomogram was constructed to integrate these factors for risk stratification.Analysis revealed significantly reduced TL1A and DR3 promoter methylation in HBV-ACLF patients, correlating with impaired liver function and coagulation parameters. PBMCs from these patients showed elevated mRNA expression of TL1A, DR3 and IL-6 compared to other groups. Methylation levels of TL1A and DR3 demonstrated high sensitivity and specificity in predicting HBV-ACLF severity. Besides, non-survivors exhibited lower TL1A/ DR3 methylation than survivors. A prognostic model integrating prothrombin activity (PTA), procalcitonin (PCT), and TL1A/DR3 methylation demonstrated excellent performance in predicting 90-day outcomes.Aberrant TL1A/DR3 promoter methylation reflects the disease severity, and can serve as potential biomarkers for the risk assessment of HBV-ACLF.
Keywords: HBV-ACLF, Methylation, Noninvasive model, prognosis, TL1A/DR3
Received: 18 Apr 2025; Accepted: 20 Jun 2025.
Copyright: © 2025 Wei, Zhang, Zhu, Tian, Xu, Fan and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Kai Wang, Qilu Hospital, Shandong University, Jinan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.